Search Results - "Patil, Rashmee"

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial by Harrison, Stephen A., Ruane, Peter J., Freilich, Bradley L., Neff, Guy, Patil, Rashmee, Behling, Cynthia A., Hu, Chen, Fong, Erica, de Temple, Brittany, Tillman, Erik J., Rolph, Timothy P., Cheng, Andrew, Yale, Kitty

“…Preclinical and clinical data suggest that fibroblast growth factor 21 (FGF21) is anti-fibrotic, improves metabolic status and has potential to treat…”
Get full text

S1388 High Prevalence of Hepatitis B Virus Susceptibility Among Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) by Kolli, Himabindu, Patil, Rashmee

Get full text

Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease by Harrison, Stephen A., Baum, Seth J., Gunn, Nadege T., Younes, Ziad H., Kohli, Anita, Patil, Rashmee, Koziel, Margaret J., Chera, Harinder, Zhao, Jeff, Chakravarthy, Manu V.

“…AXA1125 and AXA1957 are novel, orally administered endogenous metabolic modulator compositions, specifically designed to simultaneously support multiple…”
Get full text

Endoscopic Ultrasound-Guided Radiofrequency Ablation of the Pancreatic Tumors: A Promising Tool in Management of Pancreatic Tumors by Gaduputi, Vinaya, Duddempudi, Sushil, Patil, Rashmee, Changela, Kinesh

“…Objective. Radiofrequency ablation is a well-established antitumor treatment and is recognized as one of the least invasive therapeutic modalities for…”
Get full text

Non-alcoholic fatty liver disease and cardiovascular risk by Patil, Rashmee, Sood, Gagan K

“…Non-alcoholic fatty liver disease(NAFLD) is a chronic liver disease associated with insulin resistance and metabolic syndrome. The spectrum of disease ranges…”
Get full text

Endocuff-Assisted Colonoscopy-A Novel Accessory in Improving Adenoma Detection Rate: A Review of the Literature by Patil, Rashmee, Ona, Mel A, Ofori, Emmanuel, Reddy, Madhavi

“…Endocuff (Arc Medical Design) is a U.S. Food and Drug Administration-approved device that is attached like a cap to the distal tip of the colonoscope; it is…”
Get full text

LIVRQNac (AXA1125) ENHANCES INSULIN SENSITIVITY IN PRIMARY HUMAN HEPATOCYTES AND IN SUBJECTS WITH NAFLD AND T2D by Baum, Seth J., Harrison, Stephen A., Gunn, Nadege T., Younes, Ziad H., Kohli, Anita, Patil, Rashmee, Fras, Juan P., Hamill, Michael, Daou, Nadine, Zhao, Jeff, Chakravarthy, Manu V., Koziel, Margaret J.

Get full text

Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis of adrenal lesions by Patil, Rashmee

Get full text

NAFLD-related hepatocellular carcinoma: The growing challenge by Shah, Pir Ahmad, Patil, Rashmee, Harrison, Stephen A

“…Hepatocellular carcinoma (HCC) is a common cause of cancer-related mortality and morbidity worldwide. With the obesity pandemic, NAFLD-related HCC is…”
Get full text

Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir by Anand, Sury, Moshenyat, Yitzchak, Carey, Jeanne, Papafragkakis, Haris, Ona, Mel A., Patil, Rashmee, Alhaddad, Adib

“…The fixed-dose combination of Efavirenz/Emtricitabine/Tenofovir is a first-line agent for the treatment of HIV; however few cases have reported hepatotoxicity…”
Get full text

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis by Harrison, Stephen A., Bedossa, Pierre, Guy, Cynthia D., Schattenberg, Jörn M., Loomba, Rohit, Taub, Rebecca, Labriola, Dominic, Moussa, Sam E., Neff, Guy W., Rinella, Mary E., Anstee, Quentin M., Abdelmalek, Manal F., Younossi, Zobair, Baum, Seth J., Francque, Sven, Charlton, Michael R., Newsome, Philip N., Lanthier, Nicolas, Schiefke, Ingolf, Mangia, Alessandra, Pericàs, Juan M., Patil, Rashmee, Sanyal, Arun J., Noureddin, Mazen, Bansal, Meena B., Alkhouri, Naim, Castera, Laurent, Rudraraju, Madhavi, Ratziu, Vlad

“…Resmetirom is a selective agonist of THR-β. In adults with nonalcoholic steatohepatitis and fibrosis, daily resmetirom (80 mg or 100 mg) was superior to…”
Get full text

S1049 Characteristics of a Hispanic Cohort With Non-Alcoholic Fatty Liver Disease in South Texas by Rivas, Cynthia, Suarez, Andres, Gonzalez, Mariana, Machiorlatti, Michael, Patil, Rashmee

Get full text

Prevalence and Risk Factors Contributing to Low Bone Mineral Density in Men With Chronic Liver Disease: A Retrospective Study: 998 by Patel, Ruchi, Rassameehiran, Supannee, Patil, Rashmee, Jalal, Prasun, Sood, Gagan

Get full text

Efx treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis to a similar extent in NASH patients with high-risk PNPLA3 genotypes, compared to those with lowest genetic risk: a post-hoc analysis of balanced study by Tillman, Erik, Shringarpure, Reshma, Neff, Guy, Patil, Rashmee, Ruane, Peter, Freilich, Bradley, Behling, Cynthia, Fong, Erica, de Temple, Brittany, Yale, Kitty, Harrison, Stephen, Rolph, Tim

Get full text

Mo1382 - Risk of HCC in HCV Related Cirrhosis After HCV Clearance with Direct Acting Antivirals: A Systematic Review and Meta-Analysis by Rassameehiran, Supannee, Patil, Rashmee, Patel, Ruchi, Sood, Gagan K.

Get full text

Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease by Harrison, Stephen A., Baum, Seth J., Gunn, Nadege T., Younes, Ziad H., Kohli, Anita, Patil, Rashmee, Koziel, Margaret J., Chera, Harinder, Zhao, Jeff, Chakravarthy, Manu V.

Get full text

Hepatocellular Carcinoma in Patient With Non-Alcoholic Fatty Liver Without Cirrhosis: 2386 by Rapoport, Grigoriy, Castano, Juan, Al Jobori, Hussein, Nathani, Muhammed Gulzar, Patil, Rashmee, Zamir, Asif

“…Non-alcoholic fatty liver disease (NAFLD) is a diagnosis of increasing concern due to its growing prevalence. As the epidemic of NAFLD increases, so do the…”
Get full text

LBP01 - Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D) by Harrison, Stephen A., Baum, Seth J., Gunn, Nadege T., Younes, Ziad H., Kohli, Anita, Patil, Rashmee, Koziel, Margaret J., Chera, Harinder, Zhao, Jeff, Chakravarthy, Manu V.

Get full text

Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D) by Harrison, Stephen A., Baum, Seth J., Gunn, Nadege T., Younes, Ziad H., Kohli, Anita, Patil, Rashmee, Koziel, Margaret J., Chera, Harinder, Zhao, Jeff, Chakravarthy, Manu V.

Get full text

AIMS-65 Score Does Not Predict In-Hospital Mortality or ICU Length of Stay in Patients Admitted to ICU With Peptic Ulcer Bleeding: 2280 by Patil, Rashmee, Ona, Mel A., Papafragkakis, Charilaos, Anand, Sury

Get full text